{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '10.4 Informed Consent', \"It is the Investigator's responsibility to obtain witnessed written informed consent from the\", 'patient after adequate explanation of the aims, methods, anticipated benefits and potential', 'hazards of the trial and before any trial specific procedures are performed. The patient should', 'be given a copy of the informed consent documentation. The wet ink copy of the signed and', \"dated informed consent must be retained in the institution's records and is subject to inspection\", 'by representatives of the Sponsor or representatives from regulatory agencies.', '10.5 Insurance', 'A clinical trials insurance is contracted in accordance with the local law before submission of', 'the study to the relevant authorities. A copy of the confirmation and the conditions of the', 'insurance will be handed out to every trial subject together with the informed consent form.', '10.6 Confidentiality', 'By signing this protocol, the Investigator affirms to the Sponsor that information furnished to', 'the Investigator by the Sponsor or designee will be maintained in confidence, and such', 'information will be divulged to the local Ethics Committee or similar or expert committee;', 'affiliated institution and employees, only under an appropriate understanding of confidentiality', 'with such board or committee, affiliated institution and employees. Data generated by this trial', 'will be considered confidential by the Investigator, except to the extent that it is included in a', 'publication as provided in Section 10.12 of this protocol.', '10.7 Confidentiality of Subject Records', 'By signing this protocol, the Investigator agrees that the Sponsor (or designee), EC, or', 'regulatory authority representatives may consult and/or copy trial documents in order to verify', 'worksheet/case report form data. By signing the consent form, the subject agrees to this', 'process. If trial documents will be photocopied during the process of verifying worksheet/case', 'report form information, the subject will be identified by the screening or trial subject number', 'only; full names/initials will be masked prior to transmission to the Sponsor or designee.', 'By signing this protocol, the Investigator agrees to treat all subject data used and disclosed in', 'connection with this trial in accordance with all applicable privacy laws, rules and regulations.', '10.8 Confidentiality of Investigator Information', 'By signing this protocol, the Investigator recognizes that certain personal identifying', 'information with respect to the Investigator, and all Sub-Investigators and trial site personnel,', 'may be used and disclosed for trial management purposes, as part of regulatory submissions,', 'and as required by law. This information may include:', '1. Name, address, telephone number and e-mail address;', '2. Hospital or clinic address and telephone number;', 'Confidential', 'Page 66 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '3. Curriculum vitae or other summary of qualifications and credentials; and', '4. Other professional documentation.', \"Additionally, the investigator's name and business contact information may be included when\", 'reporting certain serious adverse events to regulatory authorities or to other Investigators. By', 'signing this protocol, the Investigator expressly consents to these uses and disclosures.', 'As this is a multicenter trial, in order to facilitate contact between Investigators, the Sponsor or', \"designee may share an Investigator's name and contact information with other participating\", 'Investigators upon request.', '10.9 Compliance with Financial Disclosure Requirements', 'The Investigator/Sub-Investigator(s) agree to provide his/her financial interests in and/or', 'arrangements with the Sponsor on a Financial Disclosure Form provided by the Sponsor or', 'designee.', '10.10 Quality Management System', '10.10.1 Quality Control and Quality Assurance', 'The Standard Operating Procedures (SOPs) of the Sponsor or designee or its designated sub-', 'contractors (if applicable) are used for conduction of the trial as specified in the respective', 'agreements between the parties.', '10.10.2 Audits and Inspections', 'In case of an audit/inspection by the Sponsor or designee or an appropriate authority, the', 'investigator will make all relevant documents available. If an inspection visit by a regional', 'authority is announced, the respective trial site should inform the Sponsor or designee as early', 'as possible in order to allow for an appropriate preparation and support.', '10.10.3 Monitoring', 'It is understood that an outside monitor and other authorized personnel may contact and visit', 'the Investigator, and that they will be allowed direct access to source data/documents for trial-', 'related monitoring, audits, EC review and regulatory inspection. Direct access is defined as', 'permission to examine, analyse, verify and reproduce any records and reports that are', 'important to evaluation of a clinical trial. All reasonable precautions within the constraints of', \"the applicable regulatory requirement(s) to maintain the confidentiality of subjects' identities\", \"and Sponsor's proprietary information will be exercised (Guideline for Good Clinical Practice,\", 'ICH Harmonized Tripartite Guideline, adopted July 1996: Chapter 5.15.1 and 1.21,', 'respectively).', \"It is the monitor's responsibility to inspect the case report forms at regular intervals throughout\", 'the trial to verify adherence to the protocol: the completeness, accuracy, and consistency of', 'the data; and adherence to Good Clinical Practice guidelines. The monitor should have access', 'Confidential', 'Page 67 of 79']\n\n###\n\n", "completion": "END"}